Trial reportAmerican journal of respiratory and critical care medicine2021
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
Open access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- The efficacy and safety of high-dose isoniazid-containing therapy for multidrug-resistant tuberculosis: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.European journal of clinical pharmacology · 2022Pooled it
- High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.American journal of respiratory and critical care medicine · 2024Trial
- Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Differential regulation of monocyte oxidative burst by isoniazid in healthy and latent tuberculosis-infected subjects.Frontiers in pharmacology · 2026Article
- Anti-TB Drugs for Drug-Sensitive and Drug-ResistantCurrent issues in molecular biology · 2025Review
- Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification.International journal of antimicrobial agents · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
- Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis.European journal of drug metabolism and pharmacokinetics · 2024Review
- The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.The Journal of antimicrobial chemotherapy · 2024Article
- Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification.medRxiv : the preprint server for health sciences · 2024Article
- Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.The Journal of antimicrobial chemotherapy · 2024Observational
- Management of Polypharmacy and Potential Drug-Drug Interactions in Patients with Mycobacterial Infection: A 1-Year Experience of a Multidisciplinary Outpatient Clinic.Antibiotics (Basel, Switzerland) · 2023Article
- Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development.Frontiers in pharmacology · 2023Article
- Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.The Journal of antimicrobial chemotherapy · 2022Observational
- Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.The European respiratory journal · 2022Article
- Using Isoniazid More Safely and More Effectively: The Time Is Now.American journal of respiratory and critical care medicine · 2021Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 8 institutions in 2 countries.
Kamunkhwala GausiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-9002-8087
Elisa H IgnatiusDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Xin SunHarvard T.H. Chan School of Public Health, Boston, Massachusetts.
Soyeon KimFrontier Science Foundation, Brookline Massachusetts.
Laura MoranSocial and Scientific Systems, a DLH Company, Silver Spring, Maryland.
Lubbe WiesnerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Florian von Groote-BidlingmaierTASK Applied Science and Stellenbosch University, Cape Town, South Africa.
Richard HafnerDivision of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Kathleen DonahueFrontier Science Foundation, Amherst, New York; and.
Naadira VankerTASK Applied Science and Stellenbosch University, Cape Town, South Africa.
Susan L RosenkranzHarvard T.H. Chan School of Public Health, Boston, Massachusetts.
Susan SwindellsDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Andreas H DiaconTASK Applied Science and Stellenbosch University, Cape Town, South Africa.
Eric L NuermbergerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Kelly E DooleyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Paolo DentiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-7494-079X
Johns Hopkins University · USStellenbosch University · ZAUniversity of Cape Town · ZAFrontier Science & Technology Research Foundation · USHarvard University · USNational Institute of Allergy and Infectious Diseases · USSocial and Scientific Systems (United States) · USUniversity of Nebraska Medical Center · US
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MLOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MInternational Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7MStatistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9MStellenbosch University Clinical Trial Unit, Cape Town, South AfricaUM1AI069521 · NIAID · STELLENBOSCH UNIVERSITY · PI Shaun Barnabas, Anneke Catharina Hesseling · 2012 to 2026
$21.5MClinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4MMentoring Investigators in HIV and Tuberculosis Therapeutics ResearchK24AI150349 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DOOLEY, KELLY E. · 2020 to 2025
$789kNIAID NIH HHS K24 AI150349NIAID NIH HHS U01 AI068632NIAID NIH HHS U01 AI068634NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069521NIAID NIH HHS UM1 AI106701NIGMS NIH HHS T32 GM066691
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAntitubercular AgentsArylamine N-AcetyltransferaseBacterial ProteinsColony Count, MicrobialDose-Response Relationship, DrugFemaleHumansIsoniazidMaleMicrobial Sensitivity TestsMiddle AgedOxidoreductasesSputumTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryAntitubercular AgentsArylamine N-AcetyltransferaseBacterial ProteinsInhA protein, MycobacteriumIsoniazidNAT2 protein, humanOxidoreductasesearly bactericidal activityinhA mutationisoniazid resistancephase 2 clinical trialtuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.